Literature DB >> 27288033

A longitudinal study characterising a large adult primary ciliary dyskinesia population.

Anand Shah1, Amelia Shoemark2, Stephanie J MacNeill3, Basrull Bhaludin4, Andrew Rogers5, Diana Bilton1, David M Hansell6, Robert Wilson1, Michael R Loebinger7.   

Abstract

Primary ciliary dyskinesia (PCD) in adults has not been well described. In this retrospective observational study we aimed to characterise a large adult population and identify features associated with disease progression.We retrospectively analysed 151 adult patients at a single tertiary centre at baseline and longitudinally for a median of 7 years.We found significant variation in age at diagnosis (median 23.5 years; range <1-72 years). Older age at diagnosis was associated with impaired baseline forced expiratory volume in 1 s (FEV1) (r= -0.30, p=0.01) and increased Pseudomonas aeruginosa colonisation (difference in medians 17 years (95% CI 4.5-20 years); p=0.002). Lung function decline was estimated at FEV1 decline of 0.49% predicted per year. Lung function decline was associated with ciliary ultrastructure, with microtubular defect patients having the greatest decline (p=0.04). High-resolution computed tomography (HRCT) scores of severity of bronchial wall dilatation (p<0.001) and extent of bronchiectasis (p=0.03) additionally showed evidence of modifying FEV1 decline with age.Our study reveals that a large proportion of adult PCD patients are diagnosed late, with impaired FEV1 and increased P. aeruginosa colonisation. Increased disease burden on HRCT and ciliary ultrastructure may predict progressive lung function decline. This study characterises a large adult PCD population, identifies features associated with disease progression and highlights the need for prospective trials to determine whether early diagnosis of high-risk subgroups alongside optimal management can modify disease progression.
Copyright ©ERS 2016.

Entities:  

Mesh:

Year:  2016        PMID: 27288033     DOI: 10.1183/13993003.00209-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  26 in total

1.  Primary Ciliary Dyskinesia (PCD): A genetic disorder of motile cilia.

Authors:  Margaret W Leigh; Amjad Horani; BreAnna Kinghorn; Michael G O'Connor; Maimoona A Zariwala; Michael R Knowles
Journal:  Transl Sci Rare Dis       Date:  2019-07-04

2.  High prevalence of CCDC103 p.His154Pro mutation causing primary ciliary dyskinesia disrupts protein oligomerisation and is associated with normal diagnostic investigations.

Authors:  Amelia Shoemark; Eduardo Moya; Robert A Hirst; Mitali P Patel; Evelyn A Robson; Jane Hayward; Juliet Scully; Mahmoud R Fassad; William Lamb; Miriam Schmidts; Mellisa Dixon; Ramila S Patel-King; Andrew V Rogers; Andrew Rutman; Claire L Jackson; Patricia Goggin; Bruna Rubbo; Sarah Ollosson; Siobhán Carr; Woolf Walker; Beryl Adler; Michael R Loebinger; Robert Wilson; Andrew Bush; Hywel Williams; Christopher Boustred; Lucy Jenkins; Eamonn Sheridan; Eddie M K Chung; Christopher M Watson; Thomas Cullup; Jane S Lucas; Priti Kenia; Christopher O'Callaghan; Stephen M King; Claire Hogg; Hannah M Mitchison
Journal:  Thorax       Date:  2017-08-08       Impact factor: 9.139

3.  The Primary Ciliary Dyskinesia Computed Tomography Score in Adults with Bronchiectasis: A Derivation und Validation Study.

Authors:  Jessica Rademacher; Sabine Dettmer; Jan Fuge; Jens Vogel-Claussen; Hoen-Oh Shin; Anand Shah; Paula Inês Pedro; Rob Wilson; Tobias Welte; Frank Wacker; Michael R Loebinger; Felix C Ringshausen
Journal:  Respiration       Date:  2021-04-23       Impact factor: 3.580

Review 4.  Primary Ciliary Dyskinesia: An Update on Clinical Aspects, Genetics, Diagnosis, and Future Treatment Strategies.

Authors:  Virginia Mirra; Claudius Werner; Francesca Santamaria
Journal:  Front Pediatr       Date:  2017-06-09       Impact factor: 3.418

5.  Lung structure and function similarities between primary ciliary dyskinesia and mild cystic fibrosis: a pilot study.

Authors:  Marco Maglione; Silvia Montella; Carmine Mollica; Vincenzo Carnovale; Paola Iacotucci; Fabiola De Gregorio; Antonella Tosco; Mariarosaria Cervasio; Valeria Raia; Francesca Santamaria
Journal:  Ital J Pediatr       Date:  2017-04-12       Impact factor: 2.638

6.  The international primary ciliary dyskinesia cohort (iPCD Cohort): methods and first results.

Authors:  Myrofora Goutaki; Elisabeth Maurer; Florian S Halbeisen; Israel Amirav; Angelo Barbato; Laura Behan; Mieke Boon; Carmen Casaulta; Annick Clement; Suzanne Crowley; Eric Haarman; Claire Hogg; Bulent Karadag; Cordula Koerner-Rettberg; Margaret W Leigh; Michael R Loebinger; Henryk Mazurek; Lucy Morgan; Kim G Nielsen; Heymut Omran; Nicolaus Schwerk; Sergio Scigliano; Claudius Werner; Panayiotis Yiallouros; Zorica Zivkovic; Jane S Lucas; Claudia E Kuehni
Journal:  Eur Respir J       Date:  2017-01-04       Impact factor: 16.671

7.  Computed tomography in adult patients with primary ciliary dyskinesia: Typical imaging findings.

Authors:  Sabine Dettmer; Felix Ringshausen; Jens Vogel-Claussen; Jan Fuge; Amir Faschkami; Hoen-Oh Shin; Nicolaus Schwerk; Tobias Welte; Frank Wacker; Jessica Rademacher
Journal:  PLoS One       Date:  2018-02-06       Impact factor: 3.240

8.  Primary Ciliary Dyskinesia Due to Microtubular Defects is Associated with Worse Lung Clearance Index.

Authors:  S Irving; M Dixon; M R Fassad; E Frost; J Hayward; K Kilpin; S Ollosson; A Onoufriadis; M P Patel; J Scully; S B Carr; H M Mitchison; M R Loebinger; C Hogg; A Shoemark; A Bush
Journal:  Lung       Date:  2018-01-24       Impact factor: 2.584

Review 9.  Pathogenesis, imaging and clinical characteristics of CF and non-CF bronchiectasis.

Authors:  Jürgen Schäfer; Matthias Griese; Ravishankar Chandrasekaran; Sanjay H Chotirmall; Dominik Hartl
Journal:  BMC Pulm Med       Date:  2018-05-22       Impact factor: 3.317

10.  Lung Clearance Index (LCI) is Stable in Most Primary Ciliary Dyskinesia (PCD) Patients Managed in a Specialist Centre: a Pilot Study.

Authors:  S Irving; S Carr; C Hogg; M Loebinger; A Shoemark; A Bush
Journal:  Lung       Date:  2017-06-20       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.